Literature DB >> 19450726

Surface antigens of Plasmodium falciparum gametocytes--a new class of transmission-blocking vaccine targets?

Colin J Sutherland1.   

Abstract

The re-establishment of elimination and eradication on the malaria control agenda has led to calls for renewed effort in the development of parasite transmission-blocking interventions. Vaccines are ideally suited to this task, but progress towards an anti-gamete transmission-blocking vaccine, designed to act on parasites in blood-fed mosquitoes, has been slow. Recent work has confirmed that the surface of the gametocyte-infected erythrocyte presents antigens to the host immune system, and elicits specific humoral immune responses to these antigens, termed gametocyte surface antigens (GSAs). Likely candidate molecules, including antigens encoded by sub-telomeric multi-gene families, are discussed, and a hypothetical group of parasite molecules involved in spatial and temporal signal transduction in the human host is proposed, the tropins and circadins. The next steps for development of anti-gametocyte transmission-blocking vaccines for P. falciparum and the other human malaria species are considered.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19450726     DOI: 10.1016/j.molbiopara.2009.03.007

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  28 in total

1.  Digital phantoms generated by spectral and spatial light modulators.

Authors:  Bonghwan Chon; Fuyuki Tokumasu; Ji Youn Lee; David W Allen; Joseph P Rice; Jeeseong Hwang
Journal:  J Biomed Opt       Date:  2015       Impact factor: 3.170

Review 2.  Malaria transmission blocking immunity and sexual stage vaccines for interrupting malaria transmission in Latin America.

Authors:  Myriam Arévalo-Herrera; Yezid Solarte; Catherin Marin; Mariana Santos; Jenniffer Castellanos; John C Beier; Sócrates Herrera Valencia
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-08       Impact factor: 2.743

Review 3.  Transmission-Blocking Vaccines: Old Friends and New Prospects.

Authors:  Festus K Acquah; Joshua Adjah; Kim C Williamson; Linda E Amoah
Journal:  Infect Immun       Date:  2019-05-21       Impact factor: 3.441

Review 4.  Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination.

Authors:  Teun Bousema; Chris Drakeley
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

Review 5.  Determinants of Malaria Transmission at the Population Level.

Authors:  Teun Bousema; Chris Drakeley
Journal:  Cold Spring Harb Perspect Med       Date:  2017-12-01       Impact factor: 6.915

6.  Naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs48/45 and Pfs230 in an area of seasonal transmission.

Authors:  André Lin Ouédraogo; Will Roeffen; Adrian J F Luty; Sake J de Vlas; Issa Nebie; Edith Ilboudo-Sanogo; Nadine Cuzin-Ouattara; Karina Teleen; Alfred B Tiono; Sodiomon Bienvenu Sirima; Jan-Peter Verhave; Teun Bousema; Robert Sauerwein
Journal:  Infect Immun       Date:  2011-10-03       Impact factor: 3.441

Review 7.  Gametocytogenesis in malaria parasite: commitment, development and regulation.

Authors:  Zhenyu Liu; Jun Miao; Liwang Cui
Journal:  Future Microbiol       Date:  2011-11       Impact factor: 3.165

8.  Identification of a major rif transcript common to gametocytes and sporozoites of Plasmodium falciparum.

Authors:  Christian W Wang; Steven B Mwakalinga; Colin J Sutherland; Samana Schwank; Sarah Sharp; Cornelus C Hermsen; Robert W Sauerwein; Thor G Theander; Thomas Lavstsen
Journal:  Malar J       Date:  2010-05-28       Impact factor: 2.979

Review 9.  Malaria gametocytogenesis.

Authors:  David A Baker
Journal:  Mol Biochem Parasitol       Date:  2010-04-08       Impact factor: 1.759

Review 10.  Plasmodium falciparum gametocyte transit through the cutaneous microvasculature: A new target for malaria transmission blocking vaccines?

Authors:  Christian P Nixon
Journal:  Hum Vaccin Immunother       Date:  2016-05-16       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.